For years, reference drug manufacturers have tried to extend the exclusivity periods for their products with patent mazes, lifecycle management tools, and long legal battles resulting in marketing settlements. Etanercept has been the poster child for inexplicable delays in biosimilar competition in the US. With a potential launch date of 2029, Enbrel will have had … Continue reading Better Late Than Never? Sandoz Files Antitrust Lawsuit to Enable Launch of Etanercept Biosimilar